In vivo targeting and growth inhibition of the A20 murine B-cell lymphoma by an idiotype-specific peptide binder(615 views) Palmieri C, Falcone C, Iaccino E, Tuccillo FM, Gaspari M, Trimboli F, De Laurentiis A, Luberto L, Pontoriero M, Pisano A, Vecchio E, Fierro O, Panico M, Larobina M, Gargiulo S, Costa N, Dal Piaz F, Schiavone M, Arra C, Giudice A, Palma G, Barbieri A, Quinto I, Scala G
Department of Experimental and Clinical Medicine, University of Catanzaro Magna Graecia, 88100 Catanzaro, Italy
Italsistemi Biotechnology Institute, Crotone, Italy
Institute of Food Sciences National Research Council, Avellino, Italy
Institute of Biostructure and Bioimaging, National Research Council, Naples, Italy
Department of Functional and Biomorphologic Sciences, CEINGE, University Medical School of Naples Federico II, Naples, Italy
Department of Pharmaceutical Sciences, University of Salerno, Salerno, Italy
Department of Biochemistry and Medical Biotechnology, University Medical School of Naples Federico II, Naples, Italy
References: Fanale, M.A., Younes, A., Monoclonal antibodies in the treatment of non-hodgkin's lymphoma (2007) Drugs, 67 (3), pp. 333-350. , http://drugs.adisonline.com/pt/re/drugs/pdfhandler.00003495-200767030- 00002.pdf
jsessionid=F32hkjwgscJpLS6TzsVHknxJKpFXML71n2y8p17xMmmxwdJ0V5B1!- 1633365230!-949856144!8091!-1, DOI 10.2165/00003495-200767030-0000
Coiffier, B., Monoclonal antibodies in the treatment of malignant lymphomas (2008) Adv Exp Med Biol, 610, pp. 155-176
Aina, O.H., Sroka, T.C., Chen, M.L., Lam, K.S., Therapeutic cancer targeting peptides (2002) Biopolymers, 66 (3), pp. 184-199
Waldherr, C., Pless, M., Maecke, H.R., Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC (2002) J Nucl Med, 43 (5), pp. 610-616
Reubi, J.C., Waser, B., Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting (2003) European Journal of Nuclear Medicine and Molecular Imaging, 30 (5), pp. 781-793
Sun, L., Fuselier, J.A., Murphy, W.A., Coy, D.H., Antisense peptide nucleic acids conjugated to somatostatin analogs and targeted at the n-myc oncogene display enhanced cytotoxicity to human neuroblastoma IMR32 cells expressing somatostatin receptors (2002) Peptides, 23 (9), pp. 1557-1565
Mori, T., Cancer-specific ligands identified from screening of peptide-display libraries (2004) Current Pharmaceutical Design, 10 (19), pp. 2335-2343. , DOI 10.2174/1381612043383944
Cortese, R., Monaci, P., Nicosia, A., Identification of biologically active peptides using random libraries displayed on phage (1995) Curr Opin Biotechnol, 6 (1), pp. 73-80
Scott, J.K., Smith, G.P., Searching for peptide ligands with an epitope library (1990) Science, 249 (4967), pp. 386-390
Arap, W., Pasqualini, R., Ruoslahti, E., Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model (1998) Science, 279 (5349), pp. 377-380
Depraetere, H., Viaene, A., Deroo, S., Vauterin, S., Deckmyn, H., Identification of peptides, selected by phage display technology, that inhibit von Willebrand factor binding to collagen (1998) Blood, 92 (11), pp. 4207-4211
Bendandi, M., Gocke, C.D., Kobrin, C.B., Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma (1999) Nat Med, 5 (10), pp. 1171-1177
Renschler, M.F., Bhatt, R.R., Dower, W.J., Levy, R., Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma (1994) Proceedings of the National Academy of Sciences of the United States of America, 91 (9), pp. 3623-3627
Renschler, M.F., Wada, H.G., Fok, K.S., Levy, R., B-lymphoma cells are activated by peptide ligands of the antigen binding receptor or by anti-idiotypic antibody to induce extracellular acidification (1995) Cancer Res, 55 (23), pp. 5642-5647
Graner, M., Raymond, A., Romney, D., He, L., Whitesell, L., Katsanis, E., Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma (2000) Clin Cancer Res, 6 (3), pp. 909-915
Kim, K.J., Kanellopoulos-Langevin, C., Merwin, R.M., Sachs, D.H., Asofsky, R., Establishment and characterization of BALB/c lymphoma lines with B cell properties (1979) J Immunol, 122 (2), pp. 549-554
Lake, R.A., Van Der Most, R.G., A better way for a cancer cell to die (2006) N Engl J Med, 354 (23), pp. 2503-2504
Zhong, G., Smith, G.P., Berry, J., Brunham, R.C., Conformational mimicry of a chlamydial neutralization epitope on filamentous phage (1994) Journal of Biological Chemistry, 269 (39), pp. 24183-24188
Scala, G., Chen, X., Liu, W., Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera (1999) J Immunol, 162 (10), pp. 6155-6161
Stoddart, A., Dykstra, M.L., Brown, B.K., Song, W., Pierce, S.K., Brodsky, F.M., Lipid rafts unite signaling cascades with clathrin to regulate BCR internalization (2002) Immunity, 17 (4), pp. 451-462
Carey, G.B., Donjerkovic, D., Mueller, C.M., B-cell receptor and Fas-mediated signals for life and death (2000) Immunol Rev, 176, pp. 105-115
Panico, M., Lang, L., Larobina, M., One-step synthesis of 18f labeled [18f]-N-succinimidyl 4-fluorobenzoate for A20 and A20-36 peptides labeling (2009) J Labelled Comp Radiopharm, 52 (SUPPL.), pp. S200-S201
Meeker, T., Lowder, J., Cleary, M.L., Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies (1985) New England Journal of Medicine, 312 (26), pp. 1658-1665
Doenecke, A., Winnacker, E.L., Hallek, M., Rapid amplification of cDNA ends (RACE) improves the PCR-based isolation of immunoglobulin variable region genes from murine and human lymphoma cells and cell lines (1997) Leukemia, 11 (10), pp. 1787-1792
Levings, M.K., Bacchetta, R., Schulz, U., Roncarolo, M.G., The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells (2002) Int Arch Allergy Immunol, 129 (4), pp. 263-276
Serafini, P., Borrello, I., Bronte, V., Myeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression (2006) Semin Cancer Biol, 16 (1), pp. 53-65
Nowak, A.K., Lake, R.A., Marzo, A.L., Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells (2003) J Immunol, 170 (10), pp. 4905-4913
Migkou, M., Dimopoulos, M.A., Gavriatopoulou, M., Terpos, E., Applications of monoclonal antibodies for the treatment of hematological malignancies (2009) Expert Opin Biol Ther, 9 (2), pp. 207-220
Eeva, J., Pelkonen, J., Mechanisms of B cell receptor induced apoptosis (2004) Apoptosis, 9 (5), pp. 525-531. , DOI 10.1023/B:APPT.0000038032.22343.de
Vuist, W.M., Levy, R., Maloney, D.G., Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein (1994) Blood, 83 (4), pp. 899-906
Eldering, E., Vanlier, R.A.W., B-cell antigen receptor-induced apoptosis: Looking for clues (2005) Immunology Letters, 96 (2), pp. 187-194. , DOI 10.1016/j.imlet.2004.09.003, PII S016524780400255X
Berard, M., Mondiere, P., Casamayor-Palleja, M., Hennino, A., Bella, C., Defrance, T., Mitochondria connects the antigen receptor to effector caspases during B cell receptor-induced apoptosis in normal human B cells (1999) J Immunol, 163 (9), pp. 4655-4662
Herold, M.J., Kuss, A.W., Kraus, C., Berberich, I., Mitochondria-dependent caspase-9 activation is necessary for antigen receptor-mediated effector caspase activation and apoptosis in WEHI 231 lymphoma cells (2002) J Immunol, 168 (8), pp. 3902-3909
Lens, S.M., Den Drijver, B.F., Potgens, A.J., Tesselaar, K., Van Oers, M.H., Van Lier, R.A., Dissection of pathways leading to antigen receptor-induced and Fas/CD95-induced apoptosis in human B cells (1998) J Immunol, 160 (12), pp. 6083-6092
Livnah, O., Stura, E.A., Johnson, D.L., Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2.8 a (1996) Science, 273 (5274), pp. 464-471
Apetoh, L., Ghiringhelli, F., Tesniere, A., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy (2007) Nat Med, 13 (9), pp. 1050-1059
Casares, N., Pequignot, M.O., Tesniere, A., Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death (2005) J Exp Med, 202 (12), pp. 1691-1701
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G.M., Apetoh, L., Perfettini, J.-L., Castedo, M., Kroemer, G., Calreticulin exposure dictates the immunogenicity of cancer cell death (2007) Nature Medicine, 13 (1), pp. 54-61. , DOI 10.1038/nm1523, PII NM1523
Snyder, C.M., Aviszus, K., Heiser, R.A., Tonkin, D.R., Guth, A.M., Wysocki, L.J., Activation and tolerance in CD4+ T cells reactive to an immunoglobulin-variable region (2004) Journal of Experimental Medicine, 200 (1), pp. 1-11. , DOI 10.1084/jem.20031234
Zangani, M.M., Froyland, M., Qiu, G.Y., Lymphomas can develop from B cells chronically helped by idiotype-specific T cells (2007) J Exp Med, 204 (5), pp. 1181-1191
Horna, P., Cuenca, A., Cheng, F., In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity (2006) Blood, 107 (7), pp. 2871-2878
Blohm, U., Roth, E., Brommer, K., Dumrese, T., Rosenthal, F.M., Pircher, H., Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes (2002) J Immunol, 169 (10), pp. 5522-5530
Radoja, S., Saio, M., Frey, A.B., CD8+ tumor-infiltrating lymphocytes are primed for fas-mediated activation-induced cell death but are not apoptotic in situ (2001) Journal of Immunology, 166 (10), pp. 6074-6083
Aruga, A., Aruga, E., Tanigawa, K., Bishop, D.K., Sondak, V.K., Chang, A.E., Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role (1997) J Immunol, 159 (2), pp. 664-673
Terabe, M., Matsui, S., Park, J.M., Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence (2003) J Exp Med, 198 (11), pp. 1741-1752
Elpek, K.G., Lacelle, C., Singh, N.P., Yolcu, E.S., Shirwan, H., CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model (2007) J Immunol, 178 (11), pp. 6840-6848
Zenz, T., Mertens, D., Kuppers, R., Dohner, H., Stilgenbauer, S., From pathogenesis to treatment of chronic lymphocytic leukaemia (2010) Nat Rev Cancer, 10 (1), pp. 37-50
Fanale, M. A., Younes, A., Monoclonal antibodies in the treatment of non-hodgkin's lymphoma (2007) Drugs, 67 (3), pp. 333-350. , http: //drugs. adisonline. com/pt/re/drugs/pdfhandler. 00003495-200767030- 00002. pdf
Aina, O. H., Sroka, T. C., Chen, M. L., Lam, K. S., Therapeutic cancer targeting peptides (2002) Biopolymers, 66 (3), pp. 184-199
Reubi, J. C., Waser, B., Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting (2003) European Journal of Nuclear Medicine and Molecular Imaging, 30 (5), pp. 781-793
Scott, J. K., Smith, G. P., Searching for peptide ligands with an epitope library (1990) Science, 249 (4967), pp. 386-390
Renschler, M. F., Bhatt, R. R., Dower, W. J., Levy, R., Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma (1994) Proceedings of the National Academy of Sciences of the United States of America, 91 (9), pp. 3623-3627
Renschler, M. F., Wada, H. G., Fok, K. S., Levy, R., B-lymphoma cells are activated by peptide ligands of the antigen binding receptor or by anti-idiotypic antibody to induce extracellular acidification (1995) Cancer Res, 55 (23), pp. 5642-5647
Kim, K. J., Kanellopoulos-Langevin, C., Merwin, R. M., Sachs, D. H., Asofsky, R., Establishment and characterization of BALB/c lymphoma lines with B cell properties (1979) J Immunol, 122 (2), pp. 549-554
Lake, R. A., Van Der Most, R. G., A better way for a cancer cell to die (2006) N Engl J Med, 354 (23), pp. 2503-2504
Carey, G. B., Donjerkovic, D., Mueller, C. M., B-cell receptor and Fas-mediated signals for life and death (2000) Immunol Rev, 176, pp. 105-115
Levings, M. K., Bacchetta, R., Schulz, U., Roncarolo, M. G., The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells (2002) Int Arch Allergy Immunol, 129 (4), pp. 263-276
Nowak, A. K., Lake, R. A., Marzo, A. L., Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells (2003) J Immunol, 170 (10), pp. 4905-4913
Vuist, W. M., Levy, R., Maloney, D. G., Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein (1994) Blood, 83 (4), pp. 899-906
Herold, M. J., Kuss, A. W., Kraus, C., Berberich, I., Mitochondria-dependent caspase-9 activation is necessary for antigen receptor-mediated effector caspase activation and apoptosis in WEHI 231 lymphoma cells (2002) J Immunol, 168 (8), pp. 3902-3909
Lens, S. M., Den Drijver, B. F., Potgens, A. J., Tesselaar, K., Van Oers, M. H., Van Lier, R. A., Dissection of pathways leading to antigen receptor-induced and Fas/CD95-induced apoptosis in human B cells (1998) J Immunol, 160 (12), pp. 6083-6092
Snyder, C. M., Aviszus, K., Heiser, R. A., Tonkin, D. R., Guth, A. M., Wysocki, L. J., Activation and tolerance in CD4+ T cells reactive to an immunoglobulin-variable region (2004) Journal of Experimental Medicine, 200 (1), pp. 1-11. , DOI 10. 1084/jem. 20031234
Zangani, M. M., Froyland, M., Qiu, G. Y., Lymphomas can develop from B cells chronically helped by idiotype-specific T cells (2007) J Exp Med, 204 (5), pp. 1181-1191
Elpek, K. G., Lacelle, C., Singh, N. P., Yolcu, E. S., Shirwan, H., CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model (2007) J Immunol, 178 (11), pp. 6840-6848
In vivo targeting and growth inhibition of the A20 murine B-cell lymphoma by an idiotype-specific peptide binder
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(289 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote
Vitiello M, Finamore E, Falanga A, Raieta K, Cantisani M, Galdiero F, Pedone C, Galdiero M, Galdiero S * Fusion in Coq(481 views) Lecture Notes In Computer Science (ISSN: 0302-9743, 0302-974335404636319783540463634, 0302-974335402975459783540297543), 2001; 2178LNCS: 583-596. Impact Factor:0.415 ViewExport to BibTeXExport to EndNote